Kaempferol Reverses Acute Kidney Injury in Septic Model by Inhibiting NF-κB/AKT Signaling Pathway

被引:4
|
作者
Chen, Dagui [1 ]
Ma, Senlin [2 ]
Ye, Wangzheng [3 ]
Wang, Wenwen [4 ]
Sun, Da [4 ]
Shang, Fusheng [1 ]
Lin, Lili [4 ]
机构
[1] Shanghai Univ, Inst Translat Med, Shanghai 200444, Peoples R China
[2] Fudan Univ, Huashan Hosp, Dept Emergency Med, Shanghai 200040, Peoples R China
[3] JiangSu Prov XuZhou PharmaceuticalVocat Coll, Dept Pharmacol, Xuzhou 221100, Jiangsu, Peoples R China
[4] Wuxi Higher Hlth Vocat Technol Sch, Dept Pharmacol, Wuxi 214028, Jiangsu, Peoples R China
关键词
NEUROINFLAMMATION;
D O I
10.1155/2023/1353449
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sepsis is the main cause of acute kidney injury (AKI), mainly due to systemic immune dysregulation. Kaempferol (KAE) is a natural flavonoid compound with multiple biological activities including anti-inflammatory, antioxidant, and antiapoptotic properties. In this study, we constructed a sepsis-induced AKI mouse model and an LPS-induced glomerular mesangial cell (HK-2) in vitro sepsis AKI model. We found that KAE ameliorated sepsis-induced renal pathological damage, reversed renal function damage, and inhibited p-p65 and p-AKT protein expression. In addition, KAE reversed LPS-induced proliferation and inhibited apoptosis in HK-2 cells. These studies suggest that KAE reverses sepsis by inhibiting activation of the NF-kappa B/AKT pathway to reverse acute kidney injury.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Liver injury in septic mice were suppressed by a camptothecin-bile acid conjugate via inhibiting NF-κB signaling pathway
    Xiao, Lin-Xia
    Qi, Liang
    Zhang, Xiang-Li
    Zhou, Yu-Qin
    Yue, Han-Lin
    Yu, En-Dian
    Li, Qing-Yong
    LIFE SCIENCES, 2020, 257
  • [22] Ginkgetin aglycone ameliorates LPS-induced acute kidney injury by activating SIRT1 via inhibiting the NF-κB signaling pathway
    Junwei Zhang
    Suxia Yang
    Fang Chen
    Huicong Li
    Baoping Chen
    Cell & Bioscience, 7
  • [23] TAK-242 improves sepsis-associated acute kidney injury in rats by inhibiting the TLR4/NF-κB signaling pathway
    Xia, Yan-mei
    Guan, Yu-qian
    Liang, Ji-fang
    Wu, Wei-dong
    RENAL FAILURE, 2024, 46 (01)
  • [24] Sappanone a prevents diabetic kidney disease by inhibiting kidney inflammation and fibrosis via the NF-?B signaling pathway
    Wang, Zhe
    Chen, Zhida
    Wang, Xinyi
    Hu, Yepeng
    Kong, Jing
    Lai, Jiabin
    Li, Tiekun
    Hu, Bibi
    Zhang, Yikai
    Zheng, Xianan
    Liu, Xiaoxian
    Wang, Shengyao
    Ye, Shu
    Zhou, Qiao
    Zheng, Chao
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [25] Islet Transplantation Reverses Podocyte Injury in Diabetic Nephropathy or Induced by High Glucose via Inhibiting RhoA/ROCK/NF-κB Signaling Pathway
    Huang, Chongchu
    Zhou, Yi
    Huang, Hongjian
    Zheng, Yushu
    Kong, Lijun
    Zhang, Hewei
    Zhang, Yan
    Wang, Hongwei
    Yang, Mei
    Xu, Xiaona
    Chen, Bicheng
    JOURNAL OF DIABETES RESEARCH, 2021, 2021
  • [26] Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes
    Jiang, Ning
    Dong, Xiao-Peng
    Zhang, Suo-Lin
    You, Qing-Yong
    Jiang, Xing-Tao
    Zhao, Xiao-Gang
    MOLECULAR MEDICINE REPORTS, 2016, 13 (01) : 153 - 159
  • [27] Licochalcone A Attenuates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting NF-κB Activation
    Hu, Jun
    Liu, Jun
    INFLAMMATION, 2016, 39 (02) : 569 - 574
  • [28] Rhein prevents endotoxin-induced acute kidney injury by inhibiting NF-κB activities
    Yu, Chen
    Qi, Dong
    Sun, Ju-Feng
    Li, Peng
    Fan, Hua-Ying
    SCIENTIFIC REPORTS, 2015, 5
  • [29] Rhein prevents endotoxin-induced acute kidney injury by inhibiting NF-κB activities
    Chen Yu
    Dong Qi
    Ju-Feng Sun
    Peng Li
    Hua-Ying Fan
    Scientific Reports, 5
  • [30] The mechanism of nicotinamide on reducing acute lung injury by inhibiting MAPK and NF-κB signal pathway
    Qun Zhang
    Junyao Li
    Haixia Zhong
    Yanling Xu
    Molecular Medicine, 2021, 27